Compare GLBS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLBS | MDXH |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | Greece | Belgium |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 41.1M |
| IPO Year | 2010 | 2021 |
| Metric | GLBS | MDXH |
|---|---|---|
| Price | $3.07 | $0.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $7.67 |
| AVG Volume (30 Days) | 169.8K | ★ 761.2K |
| Earning Date | 06-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.06 | $30.78 |
| Revenue Next Year | $20.20 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.48 |
| 52 Week High | $3.09 | $5.33 |
| Indicator | GLBS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 80.81 | 19.20 |
| Support Level | $1.51 | N/A |
| Resistance Level | N/A | $3.79 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 96.08 | 10.40 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.